737 related articles for article (PubMed ID: 23523521)
1. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430
[TBL] [Abstract][Full Text] [Related]
3. Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital.
Aydemir H; Celebi G; Piskin N; Oztoprak N; Keskin AS; Aktas E; Sumbuloglu V; Akduman D
Jpn J Infect Dis; 2012; 65(1):66-71. PubMed ID: 22274161
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children].
Zhang TQ; Dong L; Wang ZY; Li HY
Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187
[TBL] [Abstract][Full Text] [Related]
5. [Risk factors and resistance patterns of invasive
Ge YL; Shan QW; Qiu Y; Zhou SP; Cheng YB; Wang F; Yang JW; Wan CM; Zhu Y; Xu Y; Chen MX; Lin DJ; Zhu CH; Zeng M
Zhonghua Er Ke Za Zhi; 2022 Aug; 60(8):762-768. PubMed ID: 35922185
[No Abstract] [Full Text] [Related]
6. Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant Acinetobacter baumannii infection: a case control study.
Chusri S; Silpapojakul K; McNeil E; Singkhamanan K; Chongsuvivatwong V
J Infect Chemother; 2015 Feb; 21(2):90-5. PubMed ID: 25454216
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections.
Baran G; Erbay A; Bodur H; Ongürü P; Akinci E; Balaban N; Cevik MA
Int J Infect Dis; 2008 Jan; 12(1):16-21. PubMed ID: 17513154
[TBL] [Abstract][Full Text] [Related]
8. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
[TBL] [Abstract][Full Text] [Related]
9. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy.
Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW
J Med Assoc Thai; 2011 Jul; 94(7):863-70. PubMed ID: 21774295
[TBL] [Abstract][Full Text] [Related]
11. Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in
Liu Y; Wang Q; Zhao C; Chen H; Li H; Wang H; Cares Network OBOT
J Med Microbiol; 2020 Jul; 69(7):949-959. PubMed ID: 32584215
[No Abstract] [Full Text] [Related]
12. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study.
Thatrimontrichai A; Techato C; Dissaneevate S; Janjindamai W; Maneenil G; Kritsaneepaiboon S; Tanaanantarak P
J Infect Chemother; 2016 Jul; 22(7):444-9. PubMed ID: 27229539
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.
Anunnatsiri S; Tonsawan P
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):693-703. PubMed ID: 21706949
[TBL] [Abstract][Full Text] [Related]
14. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.
Nutman A; Glick R; Temkin E; Hoshen M; Edgar R; Braun T; Carmeli Y
Clin Microbiol Infect; 2014 Dec; 20(12):O1028-34. PubMed ID: 24930471
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific.
Le Hello S; Falcot V; Lacassin F; Mikulski M; Baumann F
Scand J Infect Dis; 2010 Dec; 42(11-12):821-6. PubMed ID: 20560868
[TBL] [Abstract][Full Text] [Related]
16. Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant
Zhang Y; Xu G; Miao F; Huang W; Wang H; Wang X
Front Public Health; 2023; 11():1282413. PubMed ID: 38098829
[TBL] [Abstract][Full Text] [Related]
17. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
Shanthi M; Sekar U
J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
[TBL] [Abstract][Full Text] [Related]
18. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia.
Lemos EV; de la Hoz FP; Alvis N; Einarson TR; Quevedo E; Castañeda C; Leon Y; Amado C; Cañon O; Kawai K
Clin Microbiol Infect; 2014 Feb; 20(2):174-80. PubMed ID: 23668595
[TBL] [Abstract][Full Text] [Related]
19. [Factors associated with mortality in Acinetobacter baumannii infected intensive care unit patients].
Karabay O; Yahyaoğlu M; Oğütlü A; Sandıkçı O; Tuna N; Ceylan S
Mikrobiyol Bul; 2012 Apr; 46(2):335-7. PubMed ID: 22639324
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
